Xu Yurui, Chao Lin, Wang Jianyu, Sun Yonghong, Li Chen
Yurui Xu, Department of Breast and Thyroid, Wuxi No.2 People's, Hospital Affiliated Nanjing Medical University, Wuxi 214002, Jiangsu, China.
Lin Chao, Department of Breast and Thyroid, Wuxi No.2 People's, Hospital Affiliated Nanjing Medical University, Wuxi 214002, Jiangsu, China.
Pak J Med Sci. 2023 Sep-Oct;39(5):1355-1360. doi: 10.12669/pjms.39.5.7446.
To explore the effect of different chemotherapy schemes on the prognosis, immune function and adverse reactions of breast cancer patients with low HER-2 expression after surgery.
A retrospective analysis was carried out on the clinical data of 60 breast cancer patients with low HER-2 expression in Wuxi No.2 people's Hospital from January 2018 to December 2019. The enrolled patients were divided into two groups according to the different chemotherapy schemes. Patients in the DC group were treated with polyethylene glycol-coated liposome-encapsulated doxorubicin+cyclophosphamide, and those in the TC group were treated with TC (docetaxel+cyclophosphamide). Further comparison was performed on the difference in prognosis, immune function and adverse reaction between the two groups after different chemotherapy schemes.
After four courses of treatment, the IgG, CD4+ and CD4+/CD8+ values in the DC group after treatment were higher than those before treatment, while the IgG, CD3+ and CD4+values in the TC group after treatment were lower than those before treatment(P<0.05). Meanwhile, the IgG, CD4+ and CD4+/CD8+ values in the DC group were better than those in the TC group after treatment(P<0.05). During the treatment, the adverse reactions of leukopenia, alopecia, nausea and vomiting in the DC group were significantly lower than those in the TC group(P<0.05).
The chemotherapy combination of liposome-encapsulated doxorubicin+cyclophosphamide can significantly improve immune function and greatly reduce the occurrence of adverse reactions in early-stage breast cancer patients with low HER-2 expression after surgery. It has the same effect as docetaxel+cyclophosphamide in improving the prognosis of patients.
探讨不同化疗方案对HER-2低表达乳腺癌患者术后预后、免疫功能及不良反应的影响。
回顾性分析无锡市第二人民医院2018年1月至2019年12月收治的60例HER-2低表达乳腺癌患者的临床资料。根据化疗方案不同将入选患者分为两组。DC组患者采用聚乙二醇包封脂质体阿霉素+环磷酰胺治疗，TC组患者采用TC（多西他赛+环磷酰胺）治疗。进一步比较两组患者在不同化疗方案后的预后、免疫功能及不良反应差异。
经过四个疗程的治疗，DC组治疗后的IgG、CD4+及CD4+/CD8+值高于治疗前，而TC组治疗后的IgG、CD3+及CD4+值低于治疗前（P<0.05）。同时，DC组治疗后的IgG、CD4+及CD4+/CD8+值优于TC组（P<0.05）。治疗期间，DC组白细胞减少、脱发、恶心呕吐等不良反应明显低于TC组（P<0.05）。
脂质体阿霉素+环磷酰胺化疗方案能显著提高HER-2低表达早期乳腺癌患者术后的免疫功能，大幅降低不良反应的发生。在改善患者预后方面与多西他赛+环磷酰胺效果相当。
